剂量依赖性背柱激活驱动大鼠神经病理性疼痛模型脊髓电刺激的镇痛效应
该研究在SNI神经病理性疼痛大鼠模型中发现,以诱发电位复合动作电位阈值(ECAPT)为参考的脊髓电刺激(SCS)剂量中,1.2-1.3×ECAPT对机械和冷刺激过敏的镇痛效果最持久,而阈下剂量无效、1.4×ECAPT无额外获益,提示背柱纤维募集是SCS镇痛的关键驱动因素,ECAPT可作为临床可比的临床前给药标记。
要点
- 1.2-1.3×ECAPT的SCS剂量对机械和冷刺激过敏的镇痛效果最持久。
- 0-0.5×ECAPT阈下剂量无效,1.4×ECAPT无额外获益。
- 背柱纤维募集是SCS镇痛的关键驱动因素,ECAPT可指导临床前给药。
核心结论
- ECAP是转化相关的神经激活指标,背柱纤维募集是SCS镇痛的关键驱动因素。
- 支持以ECAPT指导给药,提升临床前刺激方案的临床相关性和标准化。
研究设计与样本
- 成年雄性Sprague-Dawley大鼠,SNI诱导神经病理性疼痛,n=25,硬膜外植入覆盖T12-L2的八触点电极。
- SCS参数50 Hz、100 µs,按个体化剂量0×ECAPT、0.5×ECAPT(开环)或1.1-1.4×ECAPT(闭环)给药。
- 另设SNI和sham对照各n=6,不植入电极也不刺激。
- 镇痛效果以机械(von Frey纤毛)和冷(丙酮)刺激的缩足反应评估。
主要发现
- 1.2-1.3×ECAPT的SCS剂量对机械和冷刺激过敏的降低最持久。
- 1.1×ECAPT效果较差,1.4×ECAPT无额外获益。
- 阈下剂量(0-0.5×ECAPT)无效。
关键数值与推荐
- ECAPT为背柱纤维激活起始的客观标志,近似感知阈值。
- SCS参数:50 Hz、100 µs;剂量分组:0×ECAPT、0.5×ECAPT、1.1-1.4×ECAPT。
临床怎么用
- 临床前SCS研究可采用ECAPT指导给药,替代基于运动阈值的刺激强度。
- 以1.2-1.3×ECAPT作为临床前SCS给药参考,避免阈下无效剂量和过高剂量无额外获益。
局限性
- 研究为大鼠SNI模型,样本量有限(n=25,对照各n=6),结论外推至临床需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spinal cord stimulation (SCS) is typically dosed to the perception threshold, defined as the onset of stimulation-induced sensations. The evoked compound action potential threshold (ECAPT) is an objective marker of dorsal column fiber activation onset. It approximates the perception threshold, and ECAPT-guided dosing improves clinical outcomes. Preclinical models are valuable for investigating the mechanisms of SCS, yet dosing strategies in animal studies commonly rely on motor threshold-based stimulation intensities, with limited translational relevance. Here, we establish a causal relationship between ECAPT, dorsal column activation, and analgesic efficacy, demonstrating for the first time that ECAPT provides a clinically comparable marker to guide preclinical SCS dosing based on neural activation. METHODS: Adult male Sprague-Dawley rats with spared nerve injury (SNI)-induced neuropathic pain (n=25) were implanted epidurally with an eight-contact lead covering T12-L2. SCS (50 Hz, 100 µs) was delivered at individualized doses of 0×ECAPT, 0.5×ECAPT (open loop), or 1.1-1.4×ECAPT (closed loop). Additional SNI and sham controls (n=6 each) received no lead implantation or stimulation. Analgesic efficacy was assessed by paw withdrawal responses to mechanical (von Frey filaments) and cold (acetone) stimuli. RESULTS: ECAPT-based SCS doses of 1.2-1.3×ECAPT achieved the most sustained reduction in mechanical and cold hypersensitivity, whereas 1.1×ECAPT was less effective and 1.4×ECAPT provided no additional benefit. Subthreshold doses (0-0.5×ECAPT) were ineffective. CONCLUSIONS: These findings validate ECAP as a translationally relevant measure of neural activation and demonstrate that dorsal column fiber recruitment is a key driver of SCS-induced analgesia, supporting ECAPT-guided dosing to enhance the clinical relevance and standardization of preclinical stimulation protocols.
引用
- Versantvoort EM, Ladner K, Mugan D, et al. Dose-dependent dorsal column activation drives analgesic effects of spinal cord stimulation in a rat model of neuropathic pain. Reg Anesth Pain Med. 2026. PMID: 42055600. doi:10.1136/rapm-2026-107607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。